Naftopidil Tablets
Function and Efficacy
Naftopidil is a selective α1 receptor antagonist that can inhibit the increase in blood pressure caused by α1 receptors. Pharmacodynamic tests have shown that this product has a hypotensive effect on a variety of hypertensive animal models, with a long duration of hypotension, and does not cause reflex tachycardia during hypotension. No obvious first-dose effect or drug resistance was observed after multiple oral administrations. The results of cardiac hemodynamic tests showed that this product can reduce the total peripheral resistance of anesthetized open-chest dogs, dilate peripheral blood vessels, and have no significant effect on cardiac output. This product can also relieve the sympathetic tension of the prostate and urethra caused by the excitement of the receptor through the α1 receptor blocking effect, reduce the intraurethral pressure, and improve symptoms such as urination disorders caused by benign prostatic hyperplasia.
Ingredients
The main ingredient is naftopidil, whose chemical name is: (±)-1-[4-(2-methoxyphenyl)-1-piperazinyl]-3-(1-naphthyloxy)-2-propanol.
| Name | Description | Content | CAS NO. | Manufacturer |
|---|---|---|---|---|
| Naftopidil dihydrochlorideIngredients |
A selective α1 receptor antagonist that can inhibit the increase in blood pressure caused by α1 receptors; it has a hypotensive effect on a variety of hypertensive animal models, with a long duration of hypotensive effect, does not cause reflex tachycardia, and has no obvious first-dose effect or drug resistance after multiple oral administrations; it can reduce the total peripheral resistance of anesthetized open-chest dogs, dilate peripheral blood vessels, and has no significant effect on cardiac output; it relieves the sympathetic tension of the prostate and urethra through the α1 receptor blocking effect, reduces the intraurethral pressure, and improves symptoms such as urination disorders caused by benign prostatic hyperplasia. More |
57149-07-2 | 13 |
Appearance
This product is white tablets
Indication
1. Used to slowly relieve urinary tract obstruction symptoms caused by benign prostatic hyperplasia (BPH). 2. Used for antihypertensive treatment of hypertension.
Usage and Dosage
1. For the treatment of urinary tract obstruction caused by benign prostatic hyperplasia (BPH): oral. The usual initial dose for adults is 25 mg (1 tablet) once a day, taken before bedtime. The dose can be adjusted appropriately according to the clinical efficacy. The maximum daily dose should not exceed 75 mg (3 tablets). Elderly patients should start with a low dose (12.5 mg/day) and pay attention to monitoring. 2. For the antihypertensive treatment of hypertension: The use of this product should be individualized according to the condition and the physician's clinical judgment. The commonly used starting dose is 25 mg (1 tablet) once, twice a day. After two weeks, the dose can be adjusted according to the degree of decrease in the patient's blood pressure. The recommended dosage range is 25~50 mg twice a day (
Adverse Reactions
The main symptoms include dizziness, vertigo on standing, heavy head, headache, tinnitus, constipation, stomach discomfort, edema, chills, increased AST and increased ALT.
Precautions
This product is contraindicated for patients who are allergic to any ingredient or have low blood pressure.
Drug Interactions
This product has a synergistic antihypertensive effect when used in combination with diuretics and antihypertensive drugs. The dosage should be reduced when they must be used together.
Storage
Store in airtight container. Valid for 36 months.
Packaging Specification
25mg
Validity Period
18 months
Manufacturer
GUIZHOU-EAKAN Pharmaceutical Co., Ltd.
-
Founded in:
1993-10-28 -
Address:
No. 964, South Section of Huaxi Avenue, High-tech Industrial Development Zone, Guiyang City, Guizhou Province -
Tax NO.:
915201152144240368 -
Registered Funds:
42 million yuan -
Website:
-
Email: